Medline Inc. (NASDAQ: MDLN) announced the pricing of an upsized secondary offering of 72.6 million shares of Class A common stock at $37.00 per share. The shares are being sold by stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a subsidiary of the Abu Dhabi Investment Authority.

The selling stockholders granted underwriters a 30-day option to purchase up to an additional 10.9 million shares. The offering is expected to close on May 28, 2026, subject to customary closing conditions.

Medline will not sell any shares in the offering and will not receive proceeds from the sale, according to the company's statement.

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are serving as global coordinators and joint bookrunning managers for the offering. Additional bookrunning managers include Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank and Evercore ISI, among others.

The offering is being conducted through a prospectus filed with the Securities and Exchange Commission. A registration statement relating to the securities was previously filed with and declared effective by the SEC.

Medline describes itself as a provider of medical-surgical products and supply chain solutions serving healthcare facilities. The Northfield, Illinois-based company employs more than 45,000 people worldwide and operates in more than 100 countries.